ReviewClinical lymphoma, myeloma & leukemia2010
Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future.
Review in Clinical lymphoma, myeloma & leukemia, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Early versus deferred treatment for smoldering multiple myeloma: a meta-analysis of randomized, controlled trials.PloS one · 2014Pooled it
- Management recommendations for kidney transplantation in patients with plasma cell dyscrasia.Kidney international · 2025Review
- Defining genomic events involved in the evolutionary trajectories of myeloma and its precursor conditions.Seminars in oncology · 2022Review
- [Imaging in smoldering (asymptomatic) multiple myeloma. Past, present and future].Der Radiologe · 2014Article
- Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.Leukemia · 2013Article
- Review
- From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011Review
- Development of early treatment strategies for high-risk myeloma precursor disease in the future.Seminars in hematology · 2011Review
- Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma.Seminars in hematology · 2011Review
- A case study progression to multiple myeloma.Clinical journal of oncology nursing · 2010Article
- Monoclonal gammopathy of undetermined significance and smoldering myeloma: new insights into pathophysiology and epidemiology.Hematology. American Society of Hematology. Education Program · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Recent studies show that multiple myeloma (MM) is consistently preceded by an asymptomatic precursor state. Smoldering MM (SMM) is a MM precursor defined by an M-protein concentration >or= 3 g/dL and/or >or= 10% bone marrow plasma cells, in the absence of end-organ damage. Compared with individuals diagnosed with monoclonal gammopathy of undetermined significance (MGUS), patients with SMM have a much higher annual risk of developing MM. However, based on clinical observations, the natural history of SMM varies greatly, from stable MGUS-like disease to highly progressive disease. Using conventional clinical markers, SMM patients can be stratified into 3 risk groups. Importantly, because of considerable molecular heterogeneity, we currently lack reliable markers to predict prognosis for individual SMM patients. Furthermore, until recently, potent drugs with reasonable toxicity profiles have not been available for the development of early MM treatment strategies. Consequently, current clinical guidelines emphasize the application of close clinical monitoring followed by treatment when the patient develops symptomatic MM. This review focuses on novel biomarkers, molecular profiles, and microenvironmental interactions of interest in myelomagenesis. We also discuss how the integration of novel biologic markers and clinical monitoring of SMM could facilitate the development of early treatment strategies for high-risk SMM patients in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.